These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30121124)

  • 1. Developments in anti-complement therapy; from disease to clinical trial.
    Harris CL; Pouw RB; Kavanagh D; Sun R; Ricklin D
    Mol Immunol; 2018 Oct; 102():89-119. PubMed ID: 30121124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compendium of current complement therapeutics.
    Zelek WM; Xie L; Morgan BP; Harris CL
    Mol Immunol; 2019 Oct; 114():341-352. PubMed ID: 31446305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding horizons in complement drug discovery: challenges and emerging strategies.
    Harris CL
    Semin Immunopathol; 2018 Jan; 40(1):125-140. PubMed ID: 28986638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New milestones ahead in complement-targeted therapy.
    Ricklin D; Lambris JD
    Semin Immunol; 2016 Jun; 28(3):208-22. PubMed ID: 27321574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory drugs and the complement system. A condensation product of metacresolsulfonic acid and formaldehyde prevents instantly the complement activation in vitro.
    Gancevici GG; Popescu C
    Arch Roum Pathol Exp Microbiol; 1989; 48(2):157-62. PubMed ID: 2634368
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement, a target for therapy in inflammatory and degenerative diseases.
    Morgan BP; Harris CL
    Nat Rev Drug Discov; 2015 Dec; 14(12):857-77. PubMed ID: 26493766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement therapeutics; history and current progress.
    Morgan BP; Harris CL
    Mol Immunol; 2003 Sep; 40(2-4):159-70. PubMed ID: 12914822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical promise of next-generation complement therapeutics.
    Mastellos DC; Ricklin D; Lambris JD
    Nat Rev Drug Discov; 2019 Sep; 18(9):707-729. PubMed ID: 31324874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactions and side reactions to drugs.
    Rother U
    Prog Allergy; 1986; 39():123-33. PubMed ID: 3562461
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological effects on the complement system. Possibilities and limitations of anti-inflammatory therapy].
    Kirschfink M
    Dtsch Med Wochenschr; 1995 Aug; 120(31-32):1087-90. PubMed ID: 7641591
    [No Abstract]   [Full Text] [Related]  

  • 13. Complement activation and inhibition in myocardial ischemia and reperfusion injury.
    Homeister JW; Lucchesi BR
    Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological manipulation of the complement system in human diseases.
    Asghar SS
    Front Biosci; 1996 Mar; 1():e15-25. PubMed ID: 9159241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New complement inhibitors; synthetic and natural products].
    Gancevici GG; Popescu C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1985; 30(3):263-75. PubMed ID: 4048755
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
    Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
    Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring.
    Ricklin D; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():10-21. PubMed ID: 28576323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.